Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
Although SARS-CoV-2 is considered a lung-tropic virus, severe COVID-19 is not just a viral pulmonary infection, clinically it is a multi-organ pathology with major coagulation abnormalities and thromboembolism events. Recently, antiphospholipid (aPL) antibodies were found increased in a large number...
Main Authors: | Christian A. Devaux, Laurence Camoin-Jau, Jean-Louis Mege, Didier Raoult |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-02-01
|
Series: | Journal of Microbiology, Immunology and Infection |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118221000074 |
Similar Items
-
Understanding the Pathophysiology of Thrombotic APS through Animal Models
by: Alex A. Gandhi, et al.
Published: (2021-03-01) -
The Risk of Thrombotic Events in Anetoderma Affecting Young Patients
by: Chiriac Anca E., et al.
Published: (2021-06-01) -
Flare of Antiphospholipid Syndrome in the Course of COVID-19
by: Alexandre Thibault Jacques Maria, et al.
Published: (2020-07-01) -
LUNGS IN ANTIPHOSPHOLIPID SYNDROME – THREE CASE REPORTS
by: Zlata Remškar
Published: (2001-05-01) -
The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year Prospective Study
by: Katja Perdan-Pirkmajer, et al.
Published: (2021-07-01)